Initial Worldwide Experience With the WATCHMAN Left Atrial Appendage System for Stroke Prevention in Atrial Fibrillation

Peter B. Sick, Gerhard Schuler, Karl Eugen Hauptmann, Eberhard Grube, Steve Yakubov, Zoltan G. Turi, Gregory Mishkel, Steve Almany, David Holmes

Research output: Contribution to journalArticle

247 Citations (Scopus)

Abstract

Objectives: This study assessed the feasibility of implanting a device in the left atrial appendage (LAA) in patients with atrial fibrillation (AF) to prevent thromboembolic stroke. Background: Meta-analyses confirmed that in cases of left atrial thrombus in nonrheumatic AF patients approximately 90% of them are in the LAA. Methods: The WATCHMAN Left Atrial Appendage System (Atritech Inc., Plymouth, Minnesota) is a nitinol device implanted percutaneously to seal the LAA. Patients were followed by clinical and transesophageal echocardiography at 45 days and 6 months with annual clinical follow-up thereafter. Results: Sixty-six patients underwent device implantation. Mean follow-up was 740 ± 341 days. At 45 days, 93% (54 of 58) devices showed successful sealing of LAA according to protocol. Two patients experienced device embolization, both successfully retrieved percutaneously. No embolizations occurred in 53 patients enrolled after modification of fixation barbs. There were 2 cardiac tamponades, 1 air embolism, and 1 delivery wire fracture (first generation) with surgical explantation but no long-term sequelae for the patient. Four patients developed a flat thrombus layer on the device at 6 months that resolved with additional anticoagulation. Two patients experienced transient ischemic attack, 1 without visible thrombus. There were 2 deaths, neither device related. Autopsy documented a stable, fully endothelialized device 9 months after implantation. No strokes occurred during follow-up despite >90% of patients with discontinuation of anticoagulation. Conclusions: Preliminary data suggest LAA occlusion with the WATCHMAN System to be safe and feasible. A randomized study is ongoing comparing oral anticoagulation with percutaneous closure.

Original languageEnglish (US)
Pages (from-to)1490-1495
Number of pages6
JournalJournal of the American College of Cardiology
Volume49
Issue number13
DOIs
StatePublished - Apr 3 2007

Fingerprint

Atrial Appendage
Atrial Fibrillation
Stroke
Equipment and Supplies
Thrombosis
Air Embolism
Cardiac Tamponade
Transient Ischemic Attack
Transesophageal Echocardiography
Feasibility Studies
Meta-Analysis
Autopsy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Initial Worldwide Experience With the WATCHMAN Left Atrial Appendage System for Stroke Prevention in Atrial Fibrillation. / Sick, Peter B.; Schuler, Gerhard; Hauptmann, Karl Eugen; Grube, Eberhard; Yakubov, Steve; Turi, Zoltan G.; Mishkel, Gregory; Almany, Steve; Holmes, David.

In: Journal of the American College of Cardiology, Vol. 49, No. 13, 03.04.2007, p. 1490-1495.

Research output: Contribution to journalArticle

Sick, Peter B. ; Schuler, Gerhard ; Hauptmann, Karl Eugen ; Grube, Eberhard ; Yakubov, Steve ; Turi, Zoltan G. ; Mishkel, Gregory ; Almany, Steve ; Holmes, David. / Initial Worldwide Experience With the WATCHMAN Left Atrial Appendage System for Stroke Prevention in Atrial Fibrillation. In: Journal of the American College of Cardiology. 2007 ; Vol. 49, No. 13. pp. 1490-1495.
@article{acae2bfc429149a6ba89a2d52869665e,
title = "Initial Worldwide Experience With the WATCHMAN Left Atrial Appendage System for Stroke Prevention in Atrial Fibrillation",
abstract = "Objectives: This study assessed the feasibility of implanting a device in the left atrial appendage (LAA) in patients with atrial fibrillation (AF) to prevent thromboembolic stroke. Background: Meta-analyses confirmed that in cases of left atrial thrombus in nonrheumatic AF patients approximately 90{\%} of them are in the LAA. Methods: The WATCHMAN Left Atrial Appendage System (Atritech Inc., Plymouth, Minnesota) is a nitinol device implanted percutaneously to seal the LAA. Patients were followed by clinical and transesophageal echocardiography at 45 days and 6 months with annual clinical follow-up thereafter. Results: Sixty-six patients underwent device implantation. Mean follow-up was 740 ± 341 days. At 45 days, 93{\%} (54 of 58) devices showed successful sealing of LAA according to protocol. Two patients experienced device embolization, both successfully retrieved percutaneously. No embolizations occurred in 53 patients enrolled after modification of fixation barbs. There were 2 cardiac tamponades, 1 air embolism, and 1 delivery wire fracture (first generation) with surgical explantation but no long-term sequelae for the patient. Four patients developed a flat thrombus layer on the device at 6 months that resolved with additional anticoagulation. Two patients experienced transient ischemic attack, 1 without visible thrombus. There were 2 deaths, neither device related. Autopsy documented a stable, fully endothelialized device 9 months after implantation. No strokes occurred during follow-up despite >90{\%} of patients with discontinuation of anticoagulation. Conclusions: Preliminary data suggest LAA occlusion with the WATCHMAN System to be safe and feasible. A randomized study is ongoing comparing oral anticoagulation with percutaneous closure.",
author = "Sick, {Peter B.} and Gerhard Schuler and Hauptmann, {Karl Eugen} and Eberhard Grube and Steve Yakubov and Turi, {Zoltan G.} and Gregory Mishkel and Steve Almany and David Holmes",
year = "2007",
month = "4",
day = "3",
doi = "10.1016/j.jacc.2007.02.035",
language = "English (US)",
volume = "49",
pages = "1490--1495",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "13",

}

TY - JOUR

T1 - Initial Worldwide Experience With the WATCHMAN Left Atrial Appendage System for Stroke Prevention in Atrial Fibrillation

AU - Sick, Peter B.

AU - Schuler, Gerhard

AU - Hauptmann, Karl Eugen

AU - Grube, Eberhard

AU - Yakubov, Steve

AU - Turi, Zoltan G.

AU - Mishkel, Gregory

AU - Almany, Steve

AU - Holmes, David

PY - 2007/4/3

Y1 - 2007/4/3

N2 - Objectives: This study assessed the feasibility of implanting a device in the left atrial appendage (LAA) in patients with atrial fibrillation (AF) to prevent thromboembolic stroke. Background: Meta-analyses confirmed that in cases of left atrial thrombus in nonrheumatic AF patients approximately 90% of them are in the LAA. Methods: The WATCHMAN Left Atrial Appendage System (Atritech Inc., Plymouth, Minnesota) is a nitinol device implanted percutaneously to seal the LAA. Patients were followed by clinical and transesophageal echocardiography at 45 days and 6 months with annual clinical follow-up thereafter. Results: Sixty-six patients underwent device implantation. Mean follow-up was 740 ± 341 days. At 45 days, 93% (54 of 58) devices showed successful sealing of LAA according to protocol. Two patients experienced device embolization, both successfully retrieved percutaneously. No embolizations occurred in 53 patients enrolled after modification of fixation barbs. There were 2 cardiac tamponades, 1 air embolism, and 1 delivery wire fracture (first generation) with surgical explantation but no long-term sequelae for the patient. Four patients developed a flat thrombus layer on the device at 6 months that resolved with additional anticoagulation. Two patients experienced transient ischemic attack, 1 without visible thrombus. There were 2 deaths, neither device related. Autopsy documented a stable, fully endothelialized device 9 months after implantation. No strokes occurred during follow-up despite >90% of patients with discontinuation of anticoagulation. Conclusions: Preliminary data suggest LAA occlusion with the WATCHMAN System to be safe and feasible. A randomized study is ongoing comparing oral anticoagulation with percutaneous closure.

AB - Objectives: This study assessed the feasibility of implanting a device in the left atrial appendage (LAA) in patients with atrial fibrillation (AF) to prevent thromboembolic stroke. Background: Meta-analyses confirmed that in cases of left atrial thrombus in nonrheumatic AF patients approximately 90% of them are in the LAA. Methods: The WATCHMAN Left Atrial Appendage System (Atritech Inc., Plymouth, Minnesota) is a nitinol device implanted percutaneously to seal the LAA. Patients were followed by clinical and transesophageal echocardiography at 45 days and 6 months with annual clinical follow-up thereafter. Results: Sixty-six patients underwent device implantation. Mean follow-up was 740 ± 341 days. At 45 days, 93% (54 of 58) devices showed successful sealing of LAA according to protocol. Two patients experienced device embolization, both successfully retrieved percutaneously. No embolizations occurred in 53 patients enrolled after modification of fixation barbs. There were 2 cardiac tamponades, 1 air embolism, and 1 delivery wire fracture (first generation) with surgical explantation but no long-term sequelae for the patient. Four patients developed a flat thrombus layer on the device at 6 months that resolved with additional anticoagulation. Two patients experienced transient ischemic attack, 1 without visible thrombus. There were 2 deaths, neither device related. Autopsy documented a stable, fully endothelialized device 9 months after implantation. No strokes occurred during follow-up despite >90% of patients with discontinuation of anticoagulation. Conclusions: Preliminary data suggest LAA occlusion with the WATCHMAN System to be safe and feasible. A randomized study is ongoing comparing oral anticoagulation with percutaneous closure.

UR - http://www.scopus.com/inward/record.url?scp=33947587475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947587475&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2007.02.035

DO - 10.1016/j.jacc.2007.02.035

M3 - Article

C2 - 17397680

AN - SCOPUS:33947587475

VL - 49

SP - 1490

EP - 1495

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 13

ER -